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Mitogenicity and release of vascular
endothelial growth factor with and
without heparin from fibrin glue
Paula K. Shireman, MD, and Howard P. Greisler, MD, Maywood and Hines, Ill,
and San Antonio, Tex 
Purpose: Fibrin glue (FG) has been used for local cytokine delivery on both vascular grafts
and angioplasty sites. We measured the diffusive release of vascular endothelial growth
factor (VEGF) and heparin from FG and the mitogenic activity of VEGF with and with-
out heparin in FG on canine endothelial cells (ECs) and smooth muscle cells (SMCs).
Methods: Release of VEGF labeled with iodine 125 and tritiated heparin from FG into
the overlying media was serially measured over 96 hours, and the data are reported as
the mean percent released ± SD. Proliferation assays measuring tritiated thymidine
incorporation were performed for ECs and SMCs plated in media with 10% serum on
FG containing various concentrations of VEGF and heparin. Media was placed on the
FG for 24 hours and removed before plating cells to minimize the effect of the released,
soluble VEGF and heparin.
Results: At 24 hours, 54% ± 1% and 58% ± 1% of the radioactive VEGF and heparin were
released, respectively, with minimal release thereafter (58% ± 1% and 66% ± 1% at 96
hours). The ECs, SMCs, or media only (no cells) was plated on FG containing radioactive
VEGF in an immediate or 24-hour delayed fashion for 72 hours to determine the percent
release of VEGF into the media with the two different methods of plating. Cell type and
the presence or absence of cells did not affect VEGF release, but there was three times more
VEGF in the media for the immediate versus delayed plating (P < .001). Without heparin,
VEGF at 100 ng/mL or more in the FG was needed to induce EC proliferation. Heparin
at 5 U/mL enhanced EC proliferation at the VEGF dose of 100 ng/mL as compared wtih
no heparin (P < .001), but not at the VEGF dose of 1000 ng/mL, which likely represents
a maximal response. With heparin at 500 U/mL, the ECs died. In contrast, VEGF, in the
presence or absence of heparin, did not affect SMC proliferation.
Conclusions: We conclude that FG with VEGF at 1000 ng/mL and heparin at 5 U/mL
is the optimal concentration for in vivo use because this may encourage EC, but not
SMC, proliferation. The VEGF at 1000 ng/mL should leave mitogenic concentrations
of VEGF intact after the initial, diffusive loss, and the addition of heparin at 5 U/mL
may enhance VEGF mitogenic activity. (J Vasc Surg 2000;31:936-43.)
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Vascular interventions such as bypass grafts and
angioplasties are commonly used to treat patients
with atherosclerosis. These procedures damage the
endothelial lining of the blood vessels, often leading
to thrombosis and intimal hyperplasia. Clinically,
endothelial cell (EC) resurfacing of vascular grafts or
of long segments of deendothelialized arteries after
endarterectomy or angioplasty does not occur. This
has led many researchers to try and develop ways to
replace the damaged EC lining.
One of these strategies involves fibrin glue (FG).
Fibrin glue has been used experimentally as an
extended delivery system for cytokines on vascular
grafts and angioplasty sites. Cytokines and heparin
can be mixed with fibrinogen before the addition of
thrombin. Thrombin cleaves the fibrinogen into
fibrin, and a matrix is created that contains the
cytokines and heparin. The body’s fibrinolytic sys-
tem slowly degrades the matrix, possibly releasing
the cytokines.
Our group has previously reported an FG system
containing fibroblast growth factor–1 (FGF-1), also
known as acidic FGF, and heparin used on grafts
implanted into the aortoiliac and thoracoabdominal
aortic positions in dogs.1,2 The FG containing FGF-
1 and heparin placed onto expanded polytetrafluo-
roethylene (EPTFE) grafts demonstrated complete
endothelial coverage at 4 weeks, which was never
seen in the control grafts. However, the inner cap-
sule thickness was also greater in the FGF-1–treated
grafts as compared with the controls. FGF-1 stimu-
lates both EC and smooth muscle cell (SMC) prolif-
eration and may cause intimal hyperplasia. Thus, an
optimized FG would theoretically maximize EC
proliferation while minimizing SMC proliferation
that may lead to intimal hyperplasia.
Our group has published two papers attempting
to optimize FGF-1 and heparin concentrations in
FG in vitro for use in the canine model.3,4 The first
report was by Kang et al3 in 1995 who plated ECs
and SMCs directly onto FG (immediate plating)
containing various concentrations of heparin and
FGF-1. The “optimal” FG from this study contained
FGF1 at 10 ng/mL and heparin at 250 U/mL.
However, when this FG formula was tested in vivo
on canine balloon-injured carotid arteries, there was
no difference in reendothelialization rates as com-
pared with the control arteries.5 We hypothesized
that released FGF-1 and heparin from the FG 
may have affected the EC and SMC proliferation
observed in the in vitro assays. This is an important
point because substances released from FG in vitro
would remain in the overlying media, whereas sub-
stances released in an animal model would be
removed by blood flow and thus, not exert a local
effect. This led to our second publication attempting
to optimize FGF-1 and heparin in FG.4 We mea-
sured the release of radioactive FGF-1 and heparin
in FG in the in vitro setting and found that 70% ±
1% of FGF-1 and 59% ± 2% of heparin are released
from the FG within the first 24 hours with minimal
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release occurring thereafter. As a result of this release
of substances from FG, we believe that delayed plat-
ing is the preferred technique for in vitro optimiza-
tion of cytokines in FG.
Vascular endothelial growth factor (VEGF) is a
cytokine that is specific for EC proliferation and
does not stimulate SMCs. Weatherford et al6 report-
ed the in vitro optimization of VEGF and heparin in
FG using immediate plating. Human aortic ECs and
SMCs were grown on FG containing various con-
centrations of VEGF and heparin. They found that
human EC proliferation was not affected by heparin
concentration and that SMC proliferation was sig-
nificantly inhibited by heparin in a dose-dependent
fashion in the FG. They concluded that the optimal
FG contained VEGF at 10 ng/mL and heparin at 50
U/mL.
Researchers of this in vitro study who used
VEGF plated the ECs and SMCs on the FG imme-
diately after polymerization; this may not accurately
reflect the in vivo situation as well as using delayed
plating. Because VEGF is highly specific for EC pro-
liferation and migration,7 we believed that this
would be a good cytokine to test for reendothelial-
ization in our canine carotid balloon injury model.
We hypothesized that altering the VEGF and
heparin ratios in FG may affect EC and SMC prolif-
eration. Therefore, the purposes of this study are to
(1) quantify the kinetics of diffusive release of VEGF
and heparin from FG in vitro, (2) design prolifera-
tion assays using the VEGF and heparin release data
from FG, (3) quantify mitogenic activity of VEGF
on ECs and SMCs when delivered by FG, and (4)
optimize VEGF and heparin concentrations in vitro
for use in the canine model.
METHODS
Animal care complied with The Guide for the
Care and Use of Laboratory Animals (Institute of
Laboratory Animal Resources, Commission on Life
Sciences, National Research Council, 1996) and the
“Principles of Laboratory Animal Care” (National
Institutes of Health publication no. 85-23, revised
1985).
The EC and SMC harvest. Adult mongrel dogs
were anesthetized with thiopental sodium (Abbott
Laboratories, Morris Plains, NJ), intubated, and ven-
tilated. Anesthesia was maintained with nitrous oxide
and halothane. Bilateral neck incisions were made.
For ECs, bilateral external jugular veins were
removed, inverted, and processed per our previously
reported protocol.5 The EC growth media contained
M-199 (Gibco, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS) (Hyclone, Logan,
Utah), FGF-1 at 5 ng/mL (American Red Cross,
Rockville, Md), bovine lung heparin at 5 U/mL
(Pharmacia & Upjohn, Kalamazoo, Mich), 100
U/mL of penicillin, and 100 µg of streptomycin
(Gibco). The EC identity was confirmed using dual
staining with factor VIII (Dako Corp, Carpenteria,
Calif) and α-actin (Sigma Chemical Company, St
Louis, Mo) antibody immunofluorescent staining.
Only EC cultures exhibiting 95% or more positive
factor VIII staining and 5% or less positive α-actin
staining were used for the proliferation assays. The
ECs were used within passages 1-4.
The SMCs were obtained from canine carotid
arteries using a previously published explant tech-
nique.3 The SMC growth media contained
Dulbecco modified Eagle medium (DMEM)
(Gibco) supplemented with 10% FBS (Hyclone), 10
mmol/L L-nonessential amino acids, 100 U/mL
penicillin, 100 µg/mL streptomycin, 100 mmol/L
L-sodium pyruvate, and 50 µg/mL gentamicin (all
from Gibco unless otherwise stated). Primary SMCs
migrating from the explants were used in all experi-
ments. The SMC identity was confirmed using
immunofluorescent staining with α-actin antibody
(Sigma Chemical Company), and only cultures
exhibiting 95% or more positive staining were used
in the proliferation assays.
The FG plate preparation. The FG was made
by reconstituting lyophilized human fibrinogen
(American Red Cross) prepared from donor-pooled
plasma with 0.9% saline solution. For modified FG,
heparin and VEGF165 (R&D Systems, Minneapolis,
Minn) were also added to obtain a solution with a
final concentration of fibrinogen at 32 mg/mL;
VEGF at 0, 10, 100, or 1000 ng/mL; and heparin
at 0, 5, 50, or 500 U/mL. Lyophilized human
thrombin (American Red Cross) was reconstituted
with 0.9% saline solution and added to all solutions
to make a final concentration of 0.32 U/mL. A
solution containing fibrinogen and thrombin only
was made and used as the negative control. Before
polymerization, the solutions were pipetted in 30-
µL aliquots into 96-well polystyrene plastic plates
(Becton Dickinson, Lincoln Park, NJ) and allowed
to completely polymerize, about 1 hour, before the
placement of cells and/or culture media into the
wells.
Release of radioactive VEGF and heparin
from FG. The FG was made as described above, but
VEGF165 labeled with iodine 125 (125I) or tritiated
heparin (both from NEN Life Sciences Products,
Boston, Mass) was added to the FG. After polymer-
ization was complete (about 1 hour), 200 µL of the
EC or SMC media, which was used in the prolifera-
tion assays, was added to the wells. The media was
removed at the specified time (VEGF 1, 4, 24, 48,
72, and 96 hours; heparin 4, 24, 48, and 96 hours)
and counted for radioactivity. There were three wells
per time point.
The FG was made with 125I-VEGF at 100 ng/mL
with heparin at 5 or 500 U/mL to measure VEGF
release. For the measurement of heparin release, triti-
ated heparin was placed in FG at a dose of 5 U/mL
with VEGF at 10 or 1000 ng/mL to determine if
VEGF concentration affected heparin release.
In addition, 30 µL of each FG solution was
pipetted into Ready Safe Scintillation Fluid
(Beckman Instruments, Inc, Fullerton, Calif) for tri-
tiated heparin or into tubes for gamma counting for
125I-VEGF in replicates of three. The average of the
30-µL FG samples represented the total counts.
Percent release of radiolabeled VEGF or heparin was
calculated by dividing the media counts from each
well by the average of the total FG counts and mul-
tiplying by 100%. Data are expressed as the mean
percent released ± SD for each time point. The 125I-
VEGF or tritiated heparin was not corrected for
decay resulting from the short duration of the exper-
iments as compared with the half-life of the isotopes
(60 days and 12.5 years, respectively).
For 125I-VEGF, after the counting of the
radioactivity within the media samples, precipitation
experiments were performed to discriminate protein
bound versus free 125I as per our previously pub-
lished protocol.4 The percent bound was calculated
by dividing the precipitate counts by the media
counts and multiplying by 100%. The data are
expressed as the mean percent bound ± SD.
The ECs or SMCs were plated on the FG an
hour after polymerization (immediate plating) or
after removing and replacing media that had been in
contact with the FG for 24 hours before cell plating
(delayed plating), to assess if the presence of cells
affected the release of substances from FG. Cells
were plated at 5000 cells per well and allowed to
grow for 72 hours before removing the media for
counting. Identical wells of FG had media only
placed on them in either an immediate or a delayed
fashion as controls.
The EC and SMC proliferation assays on FG.
Confluent cells were trypsinized and plated on FG at
5000 cells per well in 200 µL of media. The ECs were
plated in media devoid of FGF-1 and heparin (M-199,
10% FBS, penicillin, and streptomycin). The SMCs
were plated in SMC growth media (DMEM, 10%
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76% ± 1% for the 24 and 96 hour time point, respec-
tively). Media identical to that used for the SMC
proliferation assays was also placed in wells contain-
ing FG with 125I-VEGF at 100 ng/mL and heparin
at 5 U/mL, and these results were also similar to the
media released into the EC media (SMC media 125I-
VEGF release at 24 hours, 52% ± 0.4%).
Using the data above, we wanted to minimize
the concentration of released, soluble VEGF in the
media in our in vitro assays. Noting that most of the
VEGF release occurred in the first 24 hours, we
hypothesized that a 24-hour delay before cell plating
would minimize the effect of released, soluble fac-
tors. Therefore, we decided to measure the amount
of 125I-VEGF in the media over a 72-hour period
after cell plating using immediate versus delayed
plating. Both ECs and SMCs synthesize fibrinolytic
substances that may potentially degrade the fibrin
matrix and thus, may alter the release of 125I-VEGF.
Therefore we compared the release of 125I-VEGF
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FBS, L-sodium pyruvate, L-nonessential amino acids,
penicillin, streptomycin, and gentamicin). Media was
placed on the FG for 24 hours and removed before
plating cells to minimize the effect of soluble VEGF
and heparin known to be released in the first 24 hours
(delayed plating).
After plating, the cells were allowed to grow for
48 hours. Then, tritiated thymidine (NEN Life
Science Products) at 1 µCi per well was added, and
the plates were processed and counted 24 hours later
by our previously published protocol.4
During preliminary experiments, we found that
the FG itself has a very high background that was
not affected by the composition of the FG and
exhibited little variance. Therefore, every plate con-
tained wells with FG but no cells, and the average of
these wells was subtracted from the counts per
minute (CPM) of the test wells to eliminate the high
FG background. Cells plated on FG with no addi-
tives were also placed on each plate as a negative
control, and the data were normalized by dividing
the CPM of each well by the average of the negative
control wells and multiplied by 100%.
Percent of Negative Control = [(CPM – BKGave)/
(Negative Control Average CPM – BKGave)]100%
The data are expressed as the mean percent of
the negative control ± SD. All proliferation experi-
ments were performed in duplicate, and each treat-
ment had replicates of n = 6 in each experiment (n =
12 for the combined data). The observations from
the two experiments were combined to calculate the
mean of the percent of the negative control ± SD
after normalizing the data to the negative controls
from each experiment.
Statistics. Analysis of variance with Fischer Least
Square Differences was used as an adjunct test, and
unpaired Student t tests were performed. The results
for these tests were reported as significant; P was less
than .05.
RESULTS
Release of 125I-VEGF and tritiated heparin
from FG. The results of the release of VEGF and
heparin from FG are indicative of a burst effect com-
monly seen with matrix types of release systems. As
shown in Fig 1, 54% ± 1% of the 125I-VEGF in the
FG containing heparin at 5 U/mL was released into
the overlying EC media in the first 24 hours with
minimal release occurring thereafter (58% ± 1% at 96
hours for heparin at 5 U/mL). The release of 125I-
VEGF into the media with heparin at 500 U/mL in
the FG was higher than the concentration of heparin
at 5 U/mL (heparin at 500 U/mL: 68% ± 1% and
Fig 1. Release of 125I-VEGF from FG into the media.
Media was placed on FG containing 125I-VEGF at 100
ng/mL with heparin at 5 or 500 U/mL, and the release
of 125I was serially measured at 1, 4, 24, 48, 72, and 96
hours. Precipitation with trichloroacetic acid documented
78% ± 7% of 125I to be bound to the VEGF. The data are
expressed as mean ± SD of percent of VEGF in the media.
N = 3 for each observation. Error bars not seen indicate
SD less than 1%.
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from FG in the presence and absence of cells.
The SMCs, ECs, or media only (no cells) was
plated on FG containing 125I-VEGF at 100 ng/mL
with heparin at 5 U/mL in an immediate and
delayed (media changed 24 hours after FG polymer-
ization) fashion for 72 hours to determine the per-
cent release of VEGF into the media with the two
methods of plating. The cell type or absence of cells
did not affect VEGF release, but there was three
times more VEGF in the media for the immediate
versus delayed plating (P < .001, Fig 2).
After the counting, all the mediae underwent
precipitation experiments to determine the percent
of 125I that was bound to the VEGF. The mean per-
cent bound for the entire experiment was 78% ± 7%.
The results for the release of tritiated heparin at
5 U/mL from FG were comparable to the 125I-
VEGF diffusive release (Fig 3). At 24 hours, 57% ±
1% tritiated heparin was released with minimal
release thereafter (66% ± 1% at 96 hours) for the FG
containing VEGF at 10 ng/mL. The results were
similar for the FG containing VEGF at 1000 ng/mL
(58% ± 1% and 68% ± 2% for the 24 and 96 hour
time point, respectively).
The EC and SMC proliferation assays on FG.
Delayed plating of ECs and SMCs was performed on
FG to minimize the effect of the release of VEGF
and heparin that occurs within the first 24 hours.
This is an important point, because substances
released from FG in vivo will be removed by blood
flow and may not exert a local effect. Substances
released from FG in vitro will be soluble in the over-
lying media, and if the media is not removed before
cell plating, SMC and EC proliferation can be affect-
ed. The data for both EC and SMC proliferation
assays are shown in the Table.
The EC proliferation assays on FG containing
VEGF at 0, 10, 100, or 1000 ng/mL and heparin at
0, 5, 50, or 500 U/mL revealed that the maximal
VEGF effect occurred with VEGF at 1000 ng/mL
(159 ± 7), and this was not significantly changed by
the addition of heparin at 5 U/mL (FG with VEGF
at 1000 ng/mL and heparin at 5 U/mL 156 ± 10).
The addition of heparin at 5 U/mL to FG contain-
ing VEGF at 100 ng/mL did enhance EC prolifera-
Fig 2. Effect of immediate versus delayed plating on
release of 125I-VEGF from FG. Cells were plated on FG
containing 125I-VEGF at 100 ng/mL with heparin at 5
U/mL in an immediate or in a 24-hour delayed fashion,
and the release of 125I-VEGF into the media was mea-
sured 72 hours after the cells were plated. Precipitation
with trichloroacetic acid documented 78% ± 7% of 125I to
be bound to the VEGF. The data are expressed as mean ±
SD of percent of 125I-VEGF in the media. N = 3 for each
observation.
Fig 3. Release of tritiated heparin from FG into the media.
Media was placed on FG containing tritiated heparin at 5
U/mL with VEGF at 10 or 1000 ng/mL, and the release
of tritium was serially measured at 4, 24, 48, and 96 hours.
The data are expressed as mean ± SD of percent of heparin
in the media. N = 3 for each observation.
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tion as compared with VEGF at 100 ng/mL alone
(136 ± 6 vs 115 ± 4, respectively; P < .001). The
VEGF at 10 ng/mL did not induce any significant
increase in EC proliferation as compared with the
negative controls. There was little effect on EC pro-
liferation with the increase in heparin concentration
in the FG from 0 to 50 U/mL. However, heparin at
500 U/mL led to an inhibition of EC proliferation
(8 ± 3) as compared with the negative control. We
believe that this resulted from cell death.
Morphologically, in all but the groups with heparin
at 500 U/mL, the cells appeared intact, and mini-
mal cellular debris or desquamation was observed
under phase contrast microscopy. By contrast,
groups of ECs exposed to heparin at 500 U/mL
showed visible cell loss and cellular debris.
The SMC proliferation assays on FG containing
VEGF at 100 ng/mL and heparin at 0, 5, 50, or
500 U/mL were also performed. A single concen-
tration of VEGF was used because VEGF is an EC-
specific cytokine, and we were primarily interested in
comparing the effect of heparin on SMC prolifera-
tion. Heparin doses as high as 500 U/mL had little
effect on SMC proliferation when cells were plated
in a delayed fashion on FG containing VEGF. There
was no significant change in SMC proliferation with
VEGF at 100 ng/mL with or without heparin as
compared with the negative control.
DISCUSSION
Fibrin glue has many different applications.8
Previously, our group has used FGF-1 and heparin
in FG to promote endothelialization in EPTFE
grafts,1,2 but concerns over possible intimal hyper-
plasia induced by the FGF-1 proliferative effect on
SMCs make VEGF an attractive molecule for study.
The VEGF was chosen because of its specific
chemoattractant and mitogenic activity for ECs and
its lack of effect on SMCs.7 A previous study from
our laboratory with FGF-1 and heparin in FG has
shown that 70% ± 1% of FGF-1 and 59% ± 2% of
heparin is released from the FG within the first 24
hours with minimal release occurring thereafter (at
96 hours, 66% ± 1% for FGF-1 and 67% ± 1% for
heparin).4 Using immediate plating of SMCs versus
delayed plating on FG altered the proliferation rates
of the SMCs, most likely because of the increased
soluble FGF-1 and heparin in the media of the
immediate plating group. This is an important dis-
tinction, because substances released from FG in an
in vivo animal model would be removed by blood
flow and would be unlikely to exert a local effect.
Therefore, we believe that in vitro–delayed plating is
the preferred method of optimization for later use in
animal models.
With the knowledge of the importance of imme-
diate versus delayed plating, the first purpose of this
study was to measure the diffusive release of VEGF
and heparin from FG so that an in vitro proliferation
assay could be designed that minimizes the effect of
these soluble factors in the media. For FG contain-
ing 125I-VEGF 100 at ng/mL and heparin at 5
U/mL, 54% ± 1% of the 125I-VEGF was released
into the overlying media in the first 24 hours with
minimal release occurring thereafter (58% ± 1% at 96
hours). Comparable results were obtained for
heparin release from FG containing VEGF at 10
ng/mL and tritiated heparin at 5 U/mL (57% ± 1%
at 24 hours and 66% ± 1% at 96 hours). These results
are similar to our previous study in which the release
of 125I–FGF-1 and tritiated heparin from FG was
measured.4 Media only, ECs, or SMCs were plated
on the FG an hour after polymerization (immediate
plating) or after removal and replacement of media
that had been in contact with the FG for 24 hours
before cell plating (delayed plating) to assess if the
EC and SMC proliferation on FG plated in a delayed fashion*
EC SMC
VEGF ng/mL 0 10 100 1000 100
No heparin 100 ± 6 100 ± 4 115 ± 4†‡ 159 ± 7† 106 ± 3
Heparin 5 97 ± 5 100 ± 3 136 ± 6†‡ 156 ±10† 111 ± 5
Heparin 50 91 ± 7 92 ± 6 116 ± 10† 121 ± 10† 103 ± 6
Heparin 500 8 ± 3 5 ± 3 5 ± 2 2 ± 1 103 ± 6
*SMCs or ECs were plated on FG containing VEGF and heparin 24 hours after the FG was made to exclude the effect on cell growth
of the initial release of VEGF and heparin into the media. All data are normalized to the negative control (FG without VEGF or heparin)
and are expressed as mean ± SD. N = 12 for each observation.
†P < .01 versus same heparin concentration, no VEGF.
‡P < .001 VEGF at 100 ng/mL, no heparin versus VEGF at 100 ng/mL with heparin at 5 U/mL.
presence or absence of cells affected the release of
VEGF from FG. Cell type or presence had little
effect on the release of 125I-VEGF, but there was
three times more VEGF in the media of the imme-
diate plating condition as compared with the
delayed plating. This difference was highly signifi-
cant (P < .001).
Using the above data, we chose to perform our
EC and SMC proliferation assays on FG using 24-
hour delayed plating. The SMC proliferation was
not affected by heparin concentrations as high as
500 U/mL in the FG. This result is in agreement
with our earlier study using FGF-1 in FG and
delayed plating.4 In contrast are the two studies by
Kang et al3 and Weatherford et al.6 Both of these
studies used immediate plating, and the inhibition of
SMC proliferation was likely to be a result of
released, soluble heparin in the media. The VEGF at
100 ng/mL in the FG did not stimulate SMC pro-
liferation above control levels, which is consistent
with previous reports in which VEGF was demon-
strated as a specific EC mitogen.7
In contrast, canine jugular vein endothelial cells
(CJVECs) are very sensitive to heparin concentra-
tion. In the current study, EC proliferation was
slightly decreased for heparin at 50 U/mL as com-
pared with heparin at 5 U/mL, but concentrations
of 500 U/mL caused cell death. Similar results were
demonstrated in our previous FGF-1–delayed plat-
ing study.4 In contrast, Weatherford et al6 demon-
strated that the addition of heparin 50 at U/mL in
FG enhanced EC proliferation (immediate plating)
in the presence of VEGF as compared with FG con-
taining VEGF alone. Data for heparin at 500 U/mL
in FG were not shown in this paper for ECs. Kang et
al3 found that heparin as high as 500 U/mL in the
FG did not affect EC proliferation (immediate plat-
ing). The soluble heparin concentration in the study
by Kang et al3 would be higher than in this study
because of the differences induced by immediate
versus delayed cell plating. Perhaps these discrepan-
cies can be explained by the cell types used in these
studies, which may reflect differences in response by
ECs of different species or of different vascular beds.
Weatherford et al6 used human aortic ECs, and
Kang et al3 used human umbilical vein endothelial
cells, whereas we used CJVECs. We chose CJVECs
because our in vivo model is the dog, and we have
previously seeded this cell type contained within FG
onto balloon-injured canine carotid arteries.5 The
CJVEC proliferation in response to VEGF in FG
was maximal at 1000 ng/mL. Higher concentra-
tions of VEGF were used in subsequent experiments
with no further increase in CJVEC proliferation
(data not shown). Equivalent results were obtained
at a VEGF concentration of 1000 ng/mL in the
absence and presence of heparin at 5 U/mL, which
probably represents a maximal response. At the
VEGF concentration of 100 ng/mL, the addition of
heparin at 5 U/mL increased CJVEC proliferation
as compared with FG with VEGF at 100 ng/ml
without heparin (P < .001). Thus, heparin is not
essential for VEGF-induced EC proliferation, but at
lower concentrations of VEGF, heparin enhances
EC proliferation. This is in contrast to FGF-1 in FG
in which the addition of heparin is necessary to pro-
tect FGF-1 from thrombin-induced cleavage.9
The maximum VEGF-induced CJVEC prolifera-
tion in FG was 159% of control. For FGF-1, the
maximum was 228% of control.4 In our experimen-
tal system, FGF-1 is a stronger EC mitogen than
VEGF, but VEGF does not induce SMC prolifera-
tion. In the VEGF study by Weatherford et al6 the
maximum VEGF-induced EC proliferation was
1300% of control when using FG with VEGF at 10
ng/mL and heparin at 50 U/mL. There are several
possible reasons why their data showed a more vig-
orous EC proliferative response to VEGF than this
study. Weatherford et al6 used immediate plating for
their study and had a higher concentration of solu-
ble VEGF in the media. Alternatively, we used
CJVECs, and they used human aortic ECs. In both
studies human recombinant VEGF was used, so per-
haps species differences may also account for the
variance in the two studies.
This study highlights the importance of FG-
release kinetics and the importance of species differ-
ences when designing in vitro assays. However, we
cannot entirely exclude the effect of soluble VEGF in
the media, even with the delayed method of plating.
In vivo–release kinetics of FG are different than the
in vitro kinetics studied in the current work. In vivo
substances released from FG will diffuse into the
lumen and will be locally removed by blood flow.
Additionally, flowing blood may also affect substance
release from FG as compared with the static media
that overlays the FG in in vitro proliferation assays.
The use of VEGF in autologous and prosthetic
grafts is an intriguing idea. Hamden et al10 mea-
sured VEGF messenger RNA (mRNA) levels in vein
grafts placed in the femoral artery in the canine
model. At 48 hours, VEGF mRNA expression
increased 2.5-fold in the grafts as compared with
normal vein but returned to baseline at 4 weeks. In
contrast, VEGF mRNA increased 21.4-fold in the
arterial segments adjacent to the vein graft as com-
JOURNAL OF VASCULAR SURGERY
942 Shireman and Greisler May 2000
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 5 Shireman and Greisler 943
pared with normal artery and was still elevated by
6.6-fold at 4 weeks. Luo et al11 reported that
immersing vein grafts in a VEGF solution before
implantation resulted in less intimal hyperplasia than
control grafts placed in saline solution in a rabbit
carotid artery bypass graft model. Finally, Masuda et
al12 impregnated VEGF and/or basic FGF into the
gelatinous layer of polyurethane tubular grafts that
were implanted into rat aortas for 4 weeks. The
grafts with the cytokines showed greater endothelial
coverage (50%-60% for all cytokine-treated grafts) as
compared with control grafts (30% coverage). At the
midportion of the VEGF grafts, many capillaries
were seen in the neoarterial intima and in the micro-
pores, although such capillaries were rarely seen in
control or basic FGF grafts.
For in vivo use in the dog model, this study sup-
ports the use of low heparin concentrations (5
U/mL) in the FG. The concentration of VEGF
should be high enough to still be effective after the
initial, large release of VEGF exhibited by in vitro
studies. We conclude that FG with VEGF at 1000
ng/mL and heparin at 5 U/mL is the optimal con-
centration for in vivo use because this may encour-
age EC, but not SMC, proliferation. The VEGF at
1000 at ng/mL should leave mitogenic concentra-
tions of VEGF intact after the initial, diffusive loss,
and the addition of heparin at 5 U/mL may enhance
VEGF mitogenic activity. We are currently analyzing
the in vivo explant data for FG with VEGF at 1000
ng/mL and heparin at 5 U/mL in our canine bal-
loon injury carotid model. We hope that this series
of experiments may someday lead to human trials
with FG-containing cytokines and heparin that may
promote reendothelialization and reduce intimal
hyperplasia in prosthetic and autologous grafts.
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